Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1428738 | 0.99 | ALPL (0.43) | ALPLHPGDLMNARAB9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL3716283 | 0.99 | ALPL (0.43) | ALPLHPGDLMNARAB9ACYP1A2 | |
| SCHEMBL1428165 | 0.76 | NR1H2 (0.47) | ALPLLMNARAB9ACYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15310455 | 0.75 | NR1H2 (0.46) | ALPLLMNARAB9ACYP1A2ALDH1A1 | |
| SCHEMBL1429264 | 0.73 | HTR1A (0.35) | ALPLRAB9AHSD17B10TDP1L3MBTL1 | |
| SCHEMBL1428662 | 0.72 | KMT2A (0.35) | POLBMEN1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL3710166 | 0.72 | HTR1A (0.35) | ALPLRAB9AHSD17B10TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27796360 | 0.72 | HTR1A (0.35) | ALPLRAB9AHSD17B10TDP1L3MBTL1 | |
| SCHEMBL1428575 | 0.72 | MKNK1 (0.52) | MAPK14 | |
| SCHEMBL13257284 | 0.71 | KMT2A (0.44) | RAB9ACYP1A2ALDH1A1CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130310362-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2013-11-21 | — | — | US | disclosed |
| EP-2396331-B1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER IP GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| CN-101778851-B | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG | 2013-05-08 | — | — | CN | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010091824-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| CN-101778851-A | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG | 2010-07-14 | — | — | CN | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | ALPL 4427/4885HPGD 4453/4885LMNA 4312/4885 |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | ALPL 4673/4885HPGD 3694/4885LMNA 4281/4885 |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | ALPL 4673/4885HPGD 3694/4885LMNA 4281/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | ALPL 4427/4885HPGD 4453/4885LMNA 4312/4885 |
| US-20130310362-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, PIK3CD | ALPL 4644/4885HPGD 2689/4885LMNA 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.